187 related articles for article (PubMed ID: 15914363)
1. Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy.
Ishiyama K; Takami A; Okumura H; Ozaki J; Shimadoi S; Yamanaka S; Nakao S
Int J Hematol; 2005 May; 81(4):319-22. PubMed ID: 15914363
[TBL] [Abstract][Full Text] [Related]
2. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
3. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
[TBL] [Abstract][Full Text] [Related]
4. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
6. High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma.
Lossos IS; Hosein PJ; Morgensztern D; Coleman F; Escalón MP; Byrne GE; Rosenblatt JD; Walker GR
Leuk Lymphoma; 2010 Mar; 51(3):406-14. PubMed ID: 20038221
[TBL] [Abstract][Full Text] [Related]
7. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
Lazzarino M; Arcaini L; Bernasconi P; Alessandrino EP; Gargantini L; Cairoli R; Orlandi E; Astori C; Brusamolino E; Pagnucco G; Colombo AA; Calatroni S; Iacona I; Regazzi MB; Morra E
Br J Haematol; 2002 Jan; 116(1):229-35. PubMed ID: 11841421
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Zinzani PL; Stefoni V; Alinari L; Vianelli N; Baccarani M
Leuk Lymphoma; 2003 Sep; 44(9):1637-8. PubMed ID: 14565673
[No Abstract] [Full Text] [Related]
9. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
10. Primary gastric mantle cell lymphoma in a patient with long standing history of Crohn's disease.
Raderer M; Püspök A; Birkner T; Streubel B; Chott A
Leuk Lymphoma; 2004 Jul; 45(7):1459-62. PubMed ID: 15359648
[TBL] [Abstract][Full Text] [Related]
11. Severe acute thrombocytopenia following rituximab therapy.
Rosado M; Chao H; Rose M
Leuk Lymphoma; 2007 Nov; 48(11):2239-40. PubMed ID: 17926181
[No Abstract] [Full Text] [Related]
12. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
14. Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract.
Tamura S; Ohkawauchi K; Yokoyama Y; Higashidani Y; Daibata M; Hiroi M; Yamamori S; Onishi S
J Gastroenterol; 2004 Oct; 39(10):995-1000. PubMed ID: 15549454
[TBL] [Abstract][Full Text] [Related]
15. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
16. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
Kahl BS; Longo WL; Eickhoff JC; Zehnder J; Jones C; Blank J; McFarland T; Bottner W; Rezazedeh H; Werndli J; Bailey HH;
Ann Oncol; 2006 Sep; 17(9):1418-23. PubMed ID: 16766582
[TBL] [Abstract][Full Text] [Related]
17. [Clinical analysis of 140 cases of mantle cell lymphoma].
Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768
[No Abstract] [Full Text] [Related]
18. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
[TBL] [Abstract][Full Text] [Related]
19. [Primary subcutaneous mantle cell lymphoma treated successfully with THP-COP therapy].
Hisatake J; Kawakami K; Nakamaki T; Hino K; Tomoyasu S
Rinsho Ketsueki; 2002 May; 43(5):384-8. PubMed ID: 12096492
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
